SenzaGen’s Newsletter Q2 2025

Click image to view the Newsletter in browser.

SenzaGen Newsletter 2025 Q2


SenzaGen Newsletter 2025 Q2

GARD®skin is now included in OECD TG 497
We are excited to announce that the GARDskin assay (OECD TG 442E) is now included in OECD TG 497’s Defined Approaches for Skin Sensitization (DASS), bringing high performance and extended applicability to the DASS framework. The assay is part of two key Defined Approaches:

  • The “2 out of 3” DA for hazard identification
  • The Integrated Testing Strategy (ITS) for hazard identification and potency subcategorization (1A, 1B, NC).

Learn more about how GARDskin fits into TG 497.
2066 ChatGPT Image 4 juli 2025 14 40 27
Webcast: How GARDskin enhances Defined Approaches for Skin Sensitization
Watch the webcast to learn what the inclusion of GARDskin in OECD TG 497 means in practice – and how it can support your regulatory testing strategy. The webcast is now available on demand.
WATCH THE RECORDING
2063 Genomics

FDA shift highlights need for innovative, human-relevant test methods
The FDA’s recent decision to phase out mandatory animal testing in drug development marks a major regulatory step toward wider adoption of human-relevant, non-animal methods. For SenzaGen, this shift highlights the growing value of technologies like machine learning, genomics, and organoid-based testing.

Read more in the full FDA article
1332 D R

Expanded collaboration with RIFM to advance fragrance safety
Our long-standing collaboration with the Research Institute for Fragrance Materials (RIFM) continues to grow, driven by a shared commitment to non-animal methods and scientific excellence. Recent projects expand the scope of our work, including new in vitro studies in areas such as photosensitization.

Learn more about our work with RIFM

Upcoming events
🌎 World Congress 13 | Rio de Janeiro, Brazil | Aug 31-Sep 4
🌎 Eurotox 2025 | Athens, Greece | Sep 14-17
🌎 ICT 2025 | Beijing, China | Oct 15-18
🌎 ASCCT 2025 | Gaithersburg, USA | Oct 21-23